September 2026Real-world outcomes of acute myeloid leukemia patients undergoing treatment with tyrosine kinase inhibitor (TKI) therapy targeting FLT3, IDH1, or IDH2Real-World EvidencePublication summaryPublicationsAcute myeloid leukemia